Maze Therapeutics (MAZE) Tax Provisions (2024 - 2025)
Maze Therapeutics (MAZE) reported Tax Provisions of -$27.5 million for Q4 2025, down 381.89% on a YoY basis from $9.8 million in Q4 2024, and down 381.89% sequentially from $9.8 million in Q4 2024.
Maze Therapeutics (MAZE) Tax Provisions (2024 - 2025) Analysis & Trends
Maze Therapeutics (MAZE) has 2 years of Tax Provisions data on file, last reported at -$27.5 million in Q4 2025.
- For the quarter ending Q4 2025, Tax Provisions fell 381.89% year-over-year to -$27.5 million; the trailing twelve-month figure through Dec 2025 stood at -$17.8 million (changed N/A YoY), and the FY2025 full-year result was -$27.5 million, down 345.52% from the prior year.
- Tax Provisions fell to -$27.5 million in Q4 2025, from $9.8 million in the prior quarter.
- In the past five years, Tax Provisions ranged from a high of $9.8 million in Q4 2024 to a low of -$27.5 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 125,146.46 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -859,000.00 |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 31.86 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 221.50 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 104.00 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | -60.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Maze Therapeutics | 1.49 Bn | 1.49 Bn | 18.21 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -27.54 Mn |
| Dec 31, 2024 | 9.77 Mn |
| Sep 30, 2024 | -300,000.00 |
| Jun 30, 2024 | 1.73 Mn |